Bacterin International Holdings, Inc. (BIHI) Gets Approval for Listing on NYSE Amex

By @ibtimes on

Bacterin International Holdings, Inc., a biologic company that engages in the research, development, manufacturing, and commercialization of bioactive coatings for medical devices, announced that its common stock has been given the nod of approval for a listing on the NYSE Amex and has chosen Knight Capital Group as its market maker. Shares for Bacterin’s common stocks will begin trading on NYSE Amex on Monday March 7, 2011 under a new ticker symbol “BONE”.

“This is truly an eventful period in our company’s history as we proudly commence the trading of our stock on the NYSE Amex. We believe our shares will experience higher liquidity as a NYSE Amex listed company, which will raise our profile in the investment community,” said Guy Cook, founder and CEO of Bacterin. “Over 12 years ago, we launched Bacterin with the goal to create interventional therapeutic products that encourage surgeons to treat patients earlier in the disease cascade. As a result, our core technology in both biological scaffolds for tissue regeneration and antimicrobial coatings offers patients faster, safer and more effective healing results at a greatly reduced overall cost to the medical provider. Today we have an increasing commercialized product portfolio uniquely addressing current trends and needs within the healthcare industry.”

“We welcome Bacterin International Holdings, Inc. to the NYSE Euronext family of listed companies and to NYSE Amex,” said Scott Cutler, EVP and Co-Head of U.S. Listings and Cash Execution, NYSE Euronext. “Bacterin and its shareholders will benefit from superior market quality and technology, a broad array of issuer and investor services, and a global brand association. We look forward to building a strong and lasting partnership with the Company and its shareholders.”

Bacterin’s common stock will continue to trade under the symbol BIHI on the OTC Bulletin Board until March 7, 2011.

The company also recently announced that OsteoSponge®SC, its highly effective subchondrial bone void filler, is being used in high volumes in the orthopedic institution, Arkansas Surgical Hopital (ASH).

Dr. Ken Martin, an owner and principle of ASH who performed the first OsteoSponge®SC operation at the hospital commented, “Our first case could not have gone better. The procedure was very efficient and the results were impressive. We have already begun to educate our patients on the benefits of OsteoSponge®SC and suspect a nice adoption rate.”

For more information on Bacterin International, Inc and its products, visit their company website: www.bacterin.com

Join the Discussion